Few positives seen for Valeant Pharmaceuticals International Inc ahead of March 15 conference call – FINANCIAL NEWS-ecozik.com
Home / Insurance Tips / Few positives seen for Valeant Pharmaceuticals International Inc ahead of March 15 conference call

Few positives seen for Valeant Pharmaceuticals International Inc ahead of March 15 conference call

Michael Pearson may still be considered by some as the best person to run Valeant going forward, but that doesn't mean the share price has room to run higher anytime soon.

Michael Pearson may still be considered by some because the best person to run Valeant Pharmaceuticals International Inc. going forward, but that doesn’t mean the share price has room to run higher in the near future.

Investors and analysts expect Valeant will lower its 2016 revenue guidance when it holds a rescheduled business call on March 15.

However, the pharma giant still has a comparatively attractive portfolio which includes IBS drug Xifaxan, fungus treatment Jublia, consumer and phone lens assets, as well as several older resilient brands.

As a result, Mizuho analyst Irina Koffler thinks Valeant should be able to achieve single digit organic growth in 2017.

Related

About admin

Leave a Reply

Your email address will not be published. Required fields are marked *

*